Neuroptics
Irvine, US · 1 known investors
NeurOptics manufactures the NPi-300 pupillometer, a handheld medical device that measures pupil size and reactivity for critical care assessment in hospitals. The device serves neurologists, critical care specialists, and nurses in intensive care units managing neurologically ill patients.
Founders & leadership
KS
Kamran SiminouExecutive Officer, Director
JK
Joseph KianiDirector
WW
William WorthenExecutive Officer, Director
BM
Bob MellenDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$500KraisedApr 2016 · 7 investors · Other Health CareRule 506(b)
▶$500KraisedApr 2016 · 7 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kamran SiminouExecutive Officer, Director
- Bob MellenDirector
- Joseph KianiDirector
- William WorthenExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- Proceeds to insiders
- $25K
- First sale
- Apr 2016
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$50KraisedSep 2015 · 1 investors · Other Health CareRule 506(b)
▶$50KraisedSep 2015 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kamran SiminouExecutive Officer, Director
- Joseph KianiDirector
- William WorthenExecutive Officer, Director
- Bob MellenDirector
- Offering amount
- $600K
- Amount sold
- $50K
- Proceeds to insiders
- $60K
- First sale
- Aug 2015
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $319.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.